Debt to Book Value: telesisbio.com (TBIO)

Corporate company logo of Telesis Bio, Inc. (TBIO)

A stable staff of automation engineers supports the development of Telesis Bio, Inc. (TBIO), while on GURU.Markets, the company's debt-to-book capitalization ratio demonstrates financial stability, where the 3.42 mark serves as a key metric. The business relies on high-margin consumables for synthesizers, and technological superiority in the creation of bioprinters and enzymes forms a significant defensive barrier against competitors.

Telesis Bio, Inc. (TBIO) - Debts to Book Value from 04/28/2023 to 10/05/2024
Flagship merchandise of Codex DNA

Telesis Bio, Inc. (TBIO) is fighting for market share in the synthetic biology segment, facing fierce competition from industry behemoths. Financial pressure is reflected in the total liabilities-to-book value of equity ratio. This metric measures the degree of debt load and the company's dependence on the cost of borrowed funds. High values signal risks amid rising Fed rates. An analysis of this total debt-to-book capitalization chart allows for an assessment of business resilience.

Who Telesis Bio, Inc. competes with

Debts to Book Capitalization TEM (Tempus AI Inc)|QGEN - Debts to Book Capitalization|Debt to Book Value Ionis IONS|RGEN - Debt to Book Capital|Debts to Book Capitalization RNA|CRSP (CRISPR) - Debts to Book Value|Debt to Book Capitalization Ratio GeneDx Holdings Corp.|Debt to Book Capitalization Ratio ultragenyx.com|Beam Therapeutics - Debts to Book Capitalization|Debts to Book Value SRPT (Sarepta Therapeutics)|Debt to Book Capitalization Ratio TWST|Debts to Net Assets 10x TXG|Debts to Book Capitalization NTLA (Intellia Therapeutics)|STOK: Debts to Net Assets|BioLife Solutions - Debt to Book Capitalization Ratio|Debts to Net Assets Wave Life Sciences Ltd|MAZE - Debt to Book Value|Debt to Net Assets Ratio Sionna Corp|Debts to Book Capitalization Prime Medicine, Inc. (PRME)|Debt to Book Capitalization Ratio tayshagtx.com (TSHA)|Debts to Book Capitalization QURE|MeiraGTx Holdings - Debts to Net Assets|RGNX (Regenxbio) - Debt to Book Capitalization Ratio|Solid Corp (SLDB) - Debts to Book Value|Debt to Book Value Ocugen, Inc. OCGN|pacb.com (PACB) - Debt to Net Assets Ratio|BNTC: Debts to Book Capitalization|Debts to Net Assets DSGN|Debt to Book Capitalization Ratio Rocket Pharmaceuticals Inc RCKT|Debt to Book Value Ratio 4D Molecular Corp (FDMT)|Lexeo Therapeutics, Inc. - Debts to Book Capitalization|KRRO - Debt to Book Value|Debt to Book Value EDIT (Editas Medicine)|Silence Therapeutics PLC (SLN) - Debts to Net Assets|PRQR - Debt to Book Value|Codexis (CDXS) - Debt to Book Capital|Debts to Book Capitalization Sangamo Therapeutics|Debt to Book Capitalization Ratio Nautilus Biotechnology Inc|MGX (Metagenomi) - Debts to Book Capitalization|Debts to Net Assets DTIL (Precision BioSciences Inc.)|GBIO: Debt to Book Capitalization Ratio|Debts to Book Value Boundless Bio Inc BOLD|Exicure Corp (XCUR) - Debts to Book Capitalization|IMNN: Debt to Book Value Ratio|Debt to Book Capitalization Ratio phiopharma.com|Mustang Bio (MBIO) - Debt to Book Value Ratio|RNAZ (TransCode Therapeutics Inc.) - Debts to Book Capitalization|Debts to Book Capitalization Bionano (BNGO)|Debt to Book Value Applied DNA Sciences|Debt to Book Capital bluebirdbio.com (BLUE)|IPA: Debts to Book Capitalization|Omega Therapeutics Inc - Debts to Book Value|OMIC - Debt to Book Capitalization Ratio|RGLS - Debt to Book Capitalization Ratio|Debts to Book Capitalization SYRS|TCON (traconpharma.com) - Debts to Book Value|UBX: Debt to Book Capitalization Ratio